High Dose Cytarabine plus Gemtuzumab Ozogamicin for Patients with Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902
- Citation:
- Leuk Res vol 35 (3) 329-333
- Year:
- 2011
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10 CA032291, CA33601, U10 CA077658, U10 CA035279, U10 CA031946, U10 CA033601, U10 CA045389, U10 CA033601-32, U10 CA045418, U10 CA077440, U10 CA041287, U10 CA031946-28, U10 CA074811, U10 CA047642, CA31946, U10 CA003927
- Corr. Author:
- Authors:
- Richard M. Stone Barry Moser Ben Sanford Philip Schulman Jonathan E. Kolitz Steven Allen Wendy Stock Ilene Galinsky Ravi Vij Guido Marcucci David Hurd Richard A. Larson
- Networks:
- Study
- CALGB-19902
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- gemtuzumab ozogamicin, acute myeloid leukemia, cytarabine, relapse